9,601
Total Claims
$1.8M
Drug Cost
1,126
Beneficiaries
$1,596
Cost/Patient
Peer Comparison vs. 18,720 Cardiology providers
+5%
Cost per patient vs peers
$1,596 vs $1,524 avg
+16%
Brand preference vs peers
15.8% vs 13.7% avg
Brand vs Generic
84% generic
Brand: 1,514 claims · $1.5M
Generic: 8,087 claims · $260K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Apixaban | 571 | $633K |
| Rivaroxaban | 189 | $228K |
| Sacubitril/Valsartan | 168 | $208K |
| Alirocumab | 64 | $72K |
| Evolocumab | 55 | $65K |
| Evolocumab | 66 | $64K |
| Dronedarone Hcl | 47 | $43K |
| Semaglutide | 26 | $36K |
| Empagliflozin | 25 | $33K |
| Icosapent Ethyl | 54 | $25K |
| Dapagliflozin Propanediol | 20 | $18K |
| Bempedoic Acid/Ezetimibe | 18 | $16K |
| Ezetimibe | 416 | $15K |
| Nebivolol Hcl | 148 | $15K |
| Dabigatran Etexilate Mesylate | 21 | $14K |
Prescribing Profile
Patient Profile
76
Avg Age
47%
Female
1.39
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data